Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)
Radiation treatment for each patient with cancer is designed based on CT scans. We know that tumors in the chest and abdomen move when you breathe. Because of this, there can be differences between planned treatment and the treatment actually delivered to the body. Usually with radiation a safety margin is added to ensure that radiation hits the entire tumor. This can damage healthy parts of the body because the exact location of the tumor is unknown.
Magnetic resonance imaging (MRI) is a painless and safe diagnostic procedure that uses a powerful magnet and radio waves to produce detailed images of the body's organs and structures, without the use of X-rays or other radiation.
The research doctors are studying to see if the position of a tumor can be tracked using MRI scans and tracking sensors placed on the skin. MRI scans and the tracking system used to calculate the location and position of the tumor are both FDA approved technologies.
The research doctors will also use the MRI scans to evaluate any changes in your lung function during and following your radiation treatments.
In this study the participant will undergo a series of MRI scans with and without contrast dye.
This study is being funded through grants from the National Institutes of Health (NIH).
|Study Design:||Time Perspective: Prospective|
|Official Title:||Dynamic MRI for Lung Tumor Motion and Lung Function|
- Number of Participants Whose Tumor Position is Visible Within ~2mm Using Cine-MRI Scans and External Sensors [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Tumor tracking using cine-MRI and external surrogates with an accuracy of ~ 2mm.
The participants' tumor size/margins were not specficially defined as long as it was visible/measurable on the MRI.
- Number of Participants Whose Tumor Motion Could be Tracked Using Dynamic MRI w/ Contrast Post Radiation [ Time Frame: 2 years ] [ Designated as safety issue: No ]The internal margin (IM) is one half of the peak-to-peak displacement amplitude on 4D-CT images.
|Study Start Date:||November 2009|
|Study Completion Date:||October 2015|
|Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
This is a pilot study and there is only one group.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01016938
|United States, Maryland|
|Baltimore, Maryland, United States, 21201|
|Principal Investigator:||Warren D. D'Souza, PhD||UMMC MSGCC Department of Radiation Oncology|